Board and Investment Committee
Sir Nigel Rudd
Sir Nigel is an experienced Chairman of listed businesses and investor in emerging growth companies and SMEs. Over the past 25 years, he has chaired companies such as Pendragon plc, the automotive retailer; Pilkington, a manufacturer of glass and glazing systems; Alliance Boots, a global retail pharmacy; Heathrow, the UK airport; Invensys plc, an engineering firm; Business Growth Fund, an investor in growth companies; Signature Aviation plc, the aviation firm; and Meggitt plc, the aerospace and defence firm. Sir Nigel occupied a seat on the Barclays Bank Board for more than 12 years, latterly as Deputy Chairman, retiring in 2008.
Sir Nigel is currently a Non-Executive Director of Sappi Limited, a renewable resource company. Sir Nigel is best known for his role in the 1980s at Williams plc, which he turned into a FTSE 100 Company. Williams plc remained one of the largest industrial holding companies in the UK until its demerger in 2000 into two separate entities, Chubb and Kidde.
Sir Nigel is a member of the Remuneration Committee and chair the Nominations Committee
Julian Baines MBE
Non- Executive Director
Julian was Group CEO of BBI Diagnostics Group plc where he undertook a management buyout in 2000, a flotation on AIM in 2004 and was responsible for selling the business to Alere Inc. (now part of Abbott Laboratories Limited) in 2008 for circa £85 million. In December 2009, Julian became CEO of EKF Diagnostics Holdings plc and has subsequently successfully completed a number of fund raisings and the acquisition and subsequent integration of eight businesses in seven countries. In 2016, he was awarded an MBE for services to the Life Sciences industry. Julian was also Chairman of Renalytix AI plc, a spin out company from EKF Diagnostics Holdings Plc, which recently dual listed on Nasdaq Stock Exchange, at which time Julian stepped down, and has a market capitalisation of over £400 million.
Chairman of the Investment Committee
David has extensive board experience in the diagnostics and life science industry spanning 27 years, of which the last 18 has been primarily in a role as Chairman of various public and private companies. Over that period, he has enabled 12 companies to go public (directly and indirectly) and has overseen four successful exits. David has served on the Board of a number of quoted life sciences companies, including Collagen Solutions plc, Omega Diagnostics Group plc, Genedrive plc, Premaitha Health plc (now Yourgene Health plc), OptiBiotix Health plc, Venn Life Sciences plc (now Open Orphan plc), EKF Diagnostics Holdings plc, Immunodiagnostic Systems Holdings plc and BBI Holdings plc (now BBI Diagnostics Group Limited). David was a key member of the team that floated Shield Diagnostics Group plc in 1993. He became Chief Executive Officer responsible for the merger of Shield Diagnostics with Axis Biochemicals ASA of Norway in 1999 to create Axis-Shield plc. David is a Chartered Accountant, member of ICAS and has a BCom and MBA.
Malcolm is a director of several private companies involved in the medical and technology sectors, including Antoxis Limited, Plasmox Limited, Recircle Limited and OhMedics Limited, Changingday Limited and of AIM-quoted Collagen Solutions plc. Malcolm was a director of Aircraft Medical Ltd. until November 2015, when it was sold to Medtronic Limited for US$110 million. He has previously held positions as a non-executive director in public companies and was Company Secretary at Axis-Shield plc. He has a background as a corporate finance lawyer, where Malcolm was most recently a senior corporate partner with Shepherd and Wedderburn LLP.
Chief Executive Officer and member of the Investment Committee
Rob has 24 years’ experience in capital markets. Rob was most recently at Cenkos Securities plc as head of corporate finance and corporate broking in the investment funds team. Prior to this Rob has held roles as co-head of the investment funds team at Panmure Gordon (UK) Limited and executive director, head of product development in the investment trust team at JPMorgan Asset Management Limited. Rob has advised a number of Healthcare and Life Science companies including BBI Holdings plc, Collagen Solutions plc, EKF Diagnostic Holdings plc, Scancell Holdings plc, Yourgene Health plc (previously Premaitha Health plc), Immunodiagnostics Systems Holdings plc, and Omega Diagnostics plc. Rob started his career with Ernst & Young LLP in 1996 where he qualified as a chartered accountant in the investment management group.
Senior Independent Non-Executive Director
Colin has 24 years of venture capital experience. He founded Hotspur Capital Partners Limited in November 2007, which is a private investor group. He is one of the founders of the accelerate Ignite 100 Limited and is also on the board of the National Angel Co-Investment Fund set up by the British Business Bank plc. Prior to founding Hotspur, he set up the Rising Stars Growth Fund in which he completed 37 early stage investments and led two successful funding rounds with institutions. Rising Stars has returned greater than five times initial investment to investors. He joined Rising Stars after starting his venture capital career at 3i Group plc where he achieved average investment returns of 42 per cent. IRR over a period of five years. Colin currently serves on the board of directors of Caspian Learning Limited, Femeda Limited, Screenreach Group Limited, Greengage Lighting Ltd and Hotspur Capital Partners Limited. Previously, Colin has been involved with companies that floated on public markets or were acquired by large UK or US corporations.
Chief Financial Officer
Mark is a qualified accountant with significant experience in financial management, particularly in the area of publicly quoted companies. He has dealt with all aspects of public company development from bringing small companies to flotation to supervising the on-going accountancy and ensuring the good governance of international businesses. During his ten-year tenure with ViaLogy plc (now Yourgene Health plc), Mark was a key member of the team that arranged its transformation from a private US organisation to an AIM company, via a merger with Original Investments plc. He also played a major part in arranging the financial details of ViaLogy’s restructuring. Previously, after periods with ITV Network Centre and Mechanical Copyright Protection Society Limited, Mark was appointed Finance Director of Curtis Brown Group Limited, one of the UK’s leading literary agencies, in 1996, where he managed the financial implications of the management buyout in 2001. Mark is currently Chief Finance Officer of Optibiotix Health PLC and also holds board positions on a number of small private companies.
Dr. Stewart White
Chair of the Advisory Panel
and member of the Investment Committee
Stewart has recent and direct board experience of AIM quoted companies, most recently as founding CEO of Collagen Solutions plc. Current positions include Executive Chairman at Novel Technologies Holdings Limited, Chairman of The Electrospinning Company Limited, Non-Executive Director of CuanTec Limited and Visiting Professor (Technology Entrepreneurship – Biomedical Engineering) at the University of Glasgow. Stewart has 20 years’ experience in commercialisation, product development and manufacturing of medical devices, advanced biologics and active pharmaceutical ingredients. A graduate of the University of Strathclyde, Stewart holds a first class BSc (Hons) in Applied Microbiology and a Ph.D. in Bioprocessing and an MBA.